Stay updated on SubQ Efgartigimod in CIDP Clinical Trial
Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page
- CheckyesterdayChange DetectedThe page shows Revision: v3.5.4, replacing the previous v3.5.3. This indicates a minor internal update to the trial entry rather than changes to the study details or results.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedTaiwan enrollment location updated: Taoyuan District, Taiwan was removed and Taoyuan, Taiwan was added to the study's locations.SummaryDifference0.0%

- Check23 days agoChange DetectedA new Revision: v3.5.3 was added, replacing the previous Revision: v3.5.2. This indicates a small metadata update to the page, not affecting study content.SummaryDifference0.0%

- Check30 days agoChange DetectedRevision updated to v3.5.2. Previous revision v3.5.0 was removed.SummaryDifference0.0%

- Check52 days agoChange DetectedCIDP is added as a listed condition, and a Genetic and Rare Diseases Information Center resource link is included.SummaryDifference0.1%

- Check59 days agoChange Detected- Added Naples, Italy 80131 and removed Napoli, Italy 80131 from the locations list. - Publication section updated with the Lancet Neurology ADHERE study citation and DOI; Revision updated to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.